Compare Bristol-Myers Squibb Co (BMY) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs IQIYI Inc - ADR — how do they compare? Bristol-Myers Squibb Co trades at $63.74 (market cap $129.94B), while IQIYI Inc - ADR trades at $1.33 (market cap $1.30B). The key difference: Bristol-Myers Squibb Co is far larger — about 100× IQIYI Inc - ADR's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while IQIYI Inc - ADR pays none. Which is the better fit depends on your goals.
| BMY | IQ | |
|---|---|---|
Market Cap | $129.94B | $1.30B |
Sector | Health | Media |
52-Week High | $65.89 | $2.79 |
52-Week Low | $42.60 | $0.96 |
Enterprise Value | $163.92B | $2.88B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
IQ (iQIYI) trades at $1.33, down 2.21% today, with a bullish technical signal from moving averages but overbought RSI readings. Revenue declined to $27.29B in 2025, with a net loss of $206.31M, though the company beat EPS expectations in two recent quarters. Recent news highlights AI platform growth and executive changes, while analyst sentiment is mixed with 50% buy ratings.
The outlook hinges on AI-driven content innovation and cost management to reverse profitability challenges, but risks include intense competition and regulatory pressures in China. Upside potential exists if execution improves, yet near-term volatility may persist amid earnings uncertainty and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
